-

Fungicide Application at Feekes 10.5.1 Helps Increase Yield Potential

Applying Prosaro® fungicide at early flowering helps protect grain quality, yield and profitability in cereal crops

ST. LOUIS--(BUSINESS WIRE)--When warm conditions, high humidity and high moisture arrive, a perfect storm may be brewing for Fusarium head blight, or scab, to develop and infect cereal crops. Fortunately, an optimally timed fungicide application of Prosaro® fungicide at the 8.2-ounce per acre use rate can help reduce the risk of infection and protect yield potential in small grains.

“The optimal time to apply the fungicide for management of head scab is during that early flowering period, or Feekes 10.5.1,” said Bayer Cereal Expert Kevin Thorsness. “An application at that stage helps protect the florets, which appear first in the middle of the head. This application protects them during the fertilization period and early grain fill.”

An application of Prosaro fungicide at Feekes 10.5.1 not only helps provide disease protection but can also help maximize yield potential in cereal crops.

In fact, in university and Bayer trials, spring wheat fields treated with Prosaro fungicide at 8.2 ounces per acre at Feekes 10.5.1 increased yield by an average of 8 bu/A compared to untreated acres (Figure 1).

In winter wheat trials, a yield increase was also observed. Fields treated with Prosaro fungicide at 8.2 ounces per acre during the Feekes 10.5.1 growth stage demonstrated an average yield increase of 13 bu/A, compared to the untreated check (Figure 2).

“Applying Prosaro at 8.2 ounces at Feekes 10.5.1 will reduce the risk of infection while helping to increase your yield, your quality and your overall profit,” said Thorsness. “Making a fungicide application ahead of the optimal window, or a little bit after the optimal window, is still going to help maximize your yield and improve your grain quality by reducing the amount of disease infection.”

To learn more about Prosaro fungicide, contact your local Bayer Cereal Expert or visit www.prosaro.us.

Bayer is committed to bringing new technology and solutions for agriculture and non-agricultural uses. For questions concerning the availability and use of products, contact a local Bayer representative, or visit Crop Science, a division of Bayer, online at www.cropscience.bayer.us.

Visit the Bayer Connect - Social Hub for social media, recent news, blog posts, videos and more from Crop Science, a division of Bayer.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

ALWAYS READ AND FOLLOW PESTICIDE LABEL DIRECTIONS. Performance may vary, from location to location and from year to year, as local growing, soil and weather conditions may vary. Growers should evaluate data from multiple locations and years whenever possible and should consider the impacts of these conditions on the grower’s fields.

Not all products are registered in all states and may be subject to use restrictions. The distribution, sale, or use of an unregistered pesticide is a violation of federal and/or state law and is strictly prohibited. Check with your local dealer or representative for the product registration status in your state. Bayer, Bayer Cross and Prosaro® are registered trademarks of Bayer Group. For additional product information call toll-free 1-866-99-BAYER (1-866-992-2937) or visit our website at www.BayerCropScience.us. Bayer CropScience LP, 800 North Lindbergh Boulevard, St. Louis, MO 63167. ©2020 Bayer Group. All rights reserved.

Contacts

Bayer Media Hotline, 1-862-404-5118
or
Kevin Cencula
Crop Science, a division of Bayer
Tel: (919) 698-6516
Email: kevin.cencula@bayer.com

Erica Ballmer
Rhea + Kaiser
Tel: (630) 955-2514
Email: eballmer@rkconnect.com

Find more information at www.cropscience.bayer.us.

Bayer


Release Versions

Contacts

Bayer Media Hotline, 1-862-404-5118
or
Kevin Cencula
Crop Science, a division of Bayer
Tel: (919) 698-6516
Email: kevin.cencula@bayer.com

Erica Ballmer
Rhea + Kaiser
Tel: (630) 955-2514
Email: eballmer@rkconnect.com

Find more information at www.cropscience.bayer.us.

More News From Bayer

KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease

WHIPPANY, N.J.--(BUSINESS WIRE)--The Phase III study FIND-CKD (NCT05047263) — investigating the efficacy and safety of KERENDIA® (finerenone) versus placebo when added to standard of care in adult patients with non-diabetic chronic kidney disease (CKD) — has met its primary endpoint.1 The results demonstrated a statistically significant improvement versus placebo in the primary efficacy outcome of estimated glomerular filtration rate (eGFR) slope, defined as the mean annual rate of change from...

Missouri Court Grants Preliminary Approval of Roundup™ Class Settlement to Resolve Current and Future Claims

ST. LOUIS--(BUSINESS WIRE)--Today, a judge in the Circuit Court of the City of St. Louis, Missouri granted preliminary approval of a class action settlement to resolve current and potential future Roundup claims alleging non-Hodgkin lymphoma (NHL) injuries. The motion was filed by leading plaintiff law firms representing the class. “We are pleased the Court granted preliminary approval of the class settlement, which is designed to resolve current and potential future Roundup claims relating to...

New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. This updated clearance expands MRXperion’s labeled field strength compatibility to support magnetic resonance imaging (MRI) scanners with magnetic...
Back to Newsroom